Ophthalmology
Page 1 • 2 itemsGain critical insights into global ophthalmology drug development, market trends, and regulatory landscapes. Inform your pharma investment and BD strategy.
Kodiak Sciences KSI-101 Clinical Data to Be Presented at Scientific Conferences for Macular Edema Treatment
Kodiak Sciences will present KSI-101 clinical data for macular edema secondary to inflammation, with Phase 3 results expected in Q4 2026.
NAMSA and Lexitas Form Strategic Partnership for Comprehensive Ophthalmic Medical Device Development Services
NAMSA partners with Lexitas Pharma Services to offer end-to-end ophthalmic medical device development, creating single-source solution for sponsors.